EUCTR2014-005490-37-RO进行中（未招募）1 期
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 902
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Women aged = 18 years
- •Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
- •No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC
- •Representative FFPE tumor specimens in paraffin blocks (preferred) or at least
- •15 unstained slides, with an associated pathology report documenting ER, PR, and HER2 negativity
- •A tumor specimen obtained from metastatic or locally advanced disease (if applicable) must be submitted if clinically feasible
- •ECOG performance status of 0 or 1
- •Life expectancy = 12 weeks
- •Measurable disease, as defined by RECIST v1.1
- •Adequate hematologic and end-organ function defined by laboratory results obtained within 2 weeks prior to first study treatment.
- •Women of child bearing potential must agree to use adequate contraception (double barrier
- •methods of birth control or abstinence) prior to study entry, for the duration of study treatment, and for 90 days after the last dose of study treatment.
- •Patients who are not postmenopausal (= 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 228
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 122
排除标准
- •Spinal cord compression not definitively treated with surgery and/or radiation, or previously
- •diagnosed and treated spinal cord compression without evidence that disease has been
- •clinically stable for > 2 weeks prior to randomization
- •Known CNS disease, except for treated asymptomatic CNS metastases
- •Leptomeningeal disease
- •Uncontrolled pleural effusion, pericardial effusion, or ascites (indwelling drainage catheters are permitted)
- •Uncontrolled tumor-related pain
- •Uncontrolled hypercalcemia
- •Pregnancy or lactation
- •Evidence of significant uncontrolled concomitant disease that could affect compliance with
- •the protocol or interpretation of results, including significant liver disease (such as cirrhosis,
- •uncontrolled major seizure disorder, or superior vena cava syndrome)
- •Significant cardiovascular disease
- •Severe infection within 4 weeks prior to randomization, including but not limited to
- •hospitalization for complications of infection, bacteremia, or severe pneumonia
- •History of autoimmune disease (Autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and Type 1 diabetes mellitus on an stable insulin regimen may be eligible for this study)
- •Prior allogeneic stem cell or solid organ transplantation
- •History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis,
- •organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or
- •evidence of active pneumonitis on screening chest CT scan.
- •History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- •Positive test for HIV
- •Active hepatitis B or hepatitis C
- •Active tuberculosis
- •Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial.
- •Low dose steroids for nausea, adrenocortical insufficiency or orthostatic hypotension, IV contrast allergic reactions and inhaled corticosteroids are permitted.
研究者
相似试验
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-005490-37-GRF. Hoffmann-La Roche Ltd902
进行中（未招募）
1 期
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATINGTHE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPYREGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC BREAST CANCER - Ribbon-2EUCTR2006-006507-36-BEGenentech Inc.700
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerEUCTR2014-005490-37-GBF. Hoffmann-La Roche Ltd900
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-005490-37-PLF. Hoffmann-La Roche Ltd902
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864EUCTR2014-005490-37-FIF. Hoffmann-La Roche Ltd350